

LITERATURE GUIDE

VOLUME 7

RENAL MANIFESTATIONS OF FABRY'S DISEASE

Diagnosis, Pathology and Pathogenesis:

Germain DP. [Fabry disease](#). Orphanet Journal of Rare Diseases 2010,5-30

Fogo AB, Bostad L, Svarstad E et. al. [Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy \(ISGFN\)](#). Nephrol Dial Transplant (2010) 25: 2168–2177

Hughes DA, Malmenäs M, Deegan PB et. al. [Fabry International Prognostic Index: a predictive severity score for Anderson-Fabry disease](#). J Med Genet. 2012 Mar;49(3):212-20.

Valbuena C, Leitão D, Carneiro F, Oliveira JP. [Immunohistochemical diagnosis of Fabry nephropathy and localisation of globotriaosylceramide deposits in paraffin-embedded kidney tissue sections](#). Virchows Arch. 2012 Feb;460(2):211-21.

Laura Barisoni, J. Charles Jennette, Robert Colvin et. al. [Novel Quantitative Method to Evaluate Globotriaosylceramide Inclusions in Renal Peritubular Capillaries by Virtual Microscopy in Patients With Fabry Disease](#). Arch Pathol Lab Med. 2012;136:816–824

Uma Ramaswami, Behzad Najafian, Arrigo Schieppati, Michael Mauer, Daniel G. Bichet. [Assessment of Renal Pathology and Dysfunction in Children with Fabry Disease](#). Clin J Am Soc Nephrol 5:365–370, 2010.

Whitfield PD, Calvin J, Hogg S et. al. [Targeted urine microscopy in Anderson-Fabry disease: a cheap, sensitive and specific diagnostic technique](#). Nephrol Dial Transplant. 2011 Oct;26(10):3195-202.

Moore DF, Krokhn OV, Beavis RC et. al. [Proteomics of specific treatment-related alterations in Fabry disease: A strategy to identify biological abnormalities](#). PNAS 2007 ; 104 (8): 2873-78.

Sessa A, Meroni M, Battini G et. al. [Renal pathological changes in Fabry disease](#). J Inherit Metab Dis. 2001;24 Suppl 2:66-70.

Edgar G Fischer, Michael J Moore, Donna J Lager. [Fabry disease: a morphologic study of 11 cases.](#) *Modern Pathology* (2006) 19, 1295–1301.

Sessa A, Meroni M, Battini G et. al. [Evolution of renal pathology in Fabry disease.](#) *Acta Paediatr Suppl.* 2003 Dec;92(443):6-8.

Prabakaran T, Nielsen R, Larsen JV et. al. [Receptor-mediated endocytosis of \$\alpha\$ -galactosidase A in human podocytes in Fabry disease.](#) *PLoS One.* 2011;6(9):e25065.

Chévrier M, Brakch N, Céline L et. al. [Autophagosome maturation is impaired in Fabry disease.](#) *Autophagy* 2010 Jul;6(5):589-99.

Clinical features, treatment and Outcome

Warnock DG, Daina E, Remuzzi G, West M. [Enzyme Replacement Therapy and Fabry nephropathy.](#) *Clin J Am Soc Nephrol.* 2010 Feb;5(2):371-8 .

Christoph Wanner et. al. [Prognostic Indicators of Renal Disease Progression in Adults with Fabry Disease: Natural History Data from the Fabry Registry.](#) *Clin J Am Soc Nephrol* 5: 2220–2228, 2010.

Najafian B, Mauer M, Hopkin RJ, Svarstad E. [Renal complications of Fabry disease in children.](#) *Pediatr Nephrol.* 2012 Aug 17. [Epub ahead of print]

Keating GM. [Agalsidase alfa: a review of its use in the management of fabry disease.](#) *BioDrugs* 2012 Oct 1;26(5):335-54.

Jain G, Warnock DG. [Blood pressure, proteinuria and nephropathy in Fabry disease.](#) *Nephron Clin Pract* 2011;118:c43-8.

Pisani A, Visciano B, Roux GD et. al. [Enzyme replacement therapy in patients with Fabry disease: State of the art and review of the literature.](#) *Mol Genet Metab.* 2012 Aug 11. [Epub ahead of print]

Uma Ramaswami. [Update on role of agalsidase alfa in management of Fabry disease.](#) *Drug Design, Development and Therapy.* 2011;5 Pages 155 - 173.

Warnock DG, Ortiz A, Mauer M et. al. [Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.](#) *Nephrol Dial Transplant.* 2012 Mar;27(3):1042-9.

Rozenfeld P, Neumann PM. [Treatment of fabry disease: current and emerging strategies.](#) *Curr Pharm Biotechnol.* 2011 Jun;12(6):916-22.